Discover
ZVRA
Zevra Therapeutics, Inc.
13.81
2 x 10.37
2 x 17.72
bid
ask
-
0.53
3.70%
2 @ 04:00 PM
13.76 -0.05 (0.36%)
| Ytd | 54.13% | |
| 1y | 54.30% |
13.77
day range
14.48
7.16
52 week range
14.58
| Open | 14.31 | Prev Close | 14.34 | Low | 13.77 | High | 14.48 | Mkt Cap | 816.38M |
| Vol | 1.10M | Avg Vol | 1.56M | EPS | 2.01 | P/E | 6.87 | Forward P/E | -22.00 |
| Beta | 1.93 | Short Ratio | 6.51 | Inst. Own | 54.43% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-06 | 50-d Avg | 11.49 | 200-d Avg | 9.79 | 1yr Est | 20.00 |
| Income Statement | |||
| Total Revenue | 36.22M | ||
| Revenues (USD) | 36.22M | ||
| Cost of Revenue | 1.90M | ||
| Gross Profit | 34.32M | ||
| Operating Expenses | -17.82M | ||
| Research and Development Expense | 4.39M | ||
| Selling, General and Administrative Expense | 20.78M | ||
| Operating Income | 52.15M | ||
| Interest Expense | 1.71M | ||
| Income Tax Expense | 6.91M | ||
| Net Income | 37.89M | ||
| Net Income Common Stock | 37.89M | ||
| Net Income Common Stock (USD) | 37.89M | ||
| Consolidated Income | 37.89M | ||
| Earnings per Basic Share | 0.62 | ||
| Earnings per Basic Share (USD) | 0.62 | ||
| Earnings per Diluted Share | 0.60 | ||
| Earning Before Interest & Taxes (EBIT) | 46.52M | ||
| Earning Before Interest & Taxes (USD) | 46.52M | ||
| Weighted Average Shares | 58.41M | ||
| Weighted Average Shares Diluted | 60.23M | ||
| Balance Sheet | |||
| Cash and Equivalents | 95.60M | ||
| Cash and Equivalents (USD) | 95.60M | ||
| Investments | 141.17M | ||
| Investments Current | 105.02M | ||
| Investments Non-Current | 36.15M | ||
| Trade and Non-Trade Receivables | 22.10M | ||
| Current Assets | 229.97M | ||
| Property, Plant & Equipment Net | 1.52M | ||
| Total Assets | 278.58M | ||
| Debt Current | 406.00K | ||
| Total Debt | 1.15M | ||
| Current Liabilities | 47.03M | ||
| Debt Non-Current | 741.00K | ||
| Total Liabilities | 72.78M | ||
| Accumulated Retained Earnings (Deficit) | -384.17M | ||
| Accumulated Other Comprehensive Income | -1.80M | ||
| Shareholders Equity | 205.80M | ||
| Shareholders Equity (USD) | 205.80M | ||
| Assets Non-Current | 48.61M | ||
| Total Debt (USD) | 1.15M | ||
| Deferred Revenue | 22.65M | ||
| Goodwill and Intangible Assets | 10.81M | ||
| Inventory | 2.31M | ||
| Liabilities Non-Current | 25.75M | ||
| Trade and Non-Trade Payables | 11.69M | ||
| Tax Liabilities | 27.23M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 486.00K | ||
| Net Cash Flow from Financing | -52.80M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 33.19M | ||
| Capital Expenditure | 43.94M | ||
| Issuance (Purchase) of Equity Shares | 9.92M | ||
| Issuance (Repayment) of Debt Securities | -60.09M | ||
| Net Cash Flow from Investing | 79.62M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | 35.68M | ||
| Net Cash Flow from Operations | 6.14M | ||
| Effect of Exchange Rate Changes on Cash | 233.00K | ||
| Share Based Compensation | 3.11M | ||